Humacyte to file supplemental BLA for ATEV in dialysis access
Humacyte has confirmed it will file a supplemental Biologics Licence Application (BLA) with the FDA in November 2026, seeking approval of its acellular tissue engineered vessel (ATEV) for arteriovenous (AV) access in haemodialysis patients. The filing would add dialysis access as a second approved indication for the ATEV, following the product's initial FDA approval in December 2024 for extremity vascular trauma.
The Durham, North Carolina-based company said its regulatory confidence was reinforced by recent discussions with the FDA, in which it shared clinical results and a filing plan. The supplemental BLA will draw on data from three Phase 3 studies: the V012 trial in female dialysis access patients, and the previously completed V007 and V006 studies in male and female patients.
V012 results and the case against AV fistula
The V012 trial data, presented at the Society of Vascular Surgery's Vascular Annual Meeting in June 2026, reported that women who received the ATEV spent an average of three more months without a dialysis catheter compared with those who received an autologous AV fistula, the current standard of care. Catheter-free time is a clinically meaningful endpoint because indwelling catheters carry a significant risk of infection and thrombosis in a population that is already immunologically vulnerable.
Humacyte founder and chief executive Laura Niklason said the V012 data demonstrated "breakthrough outcomes" for women. The company's language has been noted; Niklason's characterisation of the results as breakthrough carries regulatory weight given that the ATEV holds FDA Fast Track designation and was the first product candidate to receive a Regenerative Medicine Advanced Therapy (RMAT) designation for AV access in haemodialysis.
The company positions the ATEV as an option for patients in whom AV fistula maturation is complicated by small vessel anatomy, diabetes, or obesity. These comorbidities are prevalent in the roughly 500,000 Americans currently dependent on haemodialysis, a population in which access failure remains a significant driver of hospitalisation and mortality.
Market context and competitive landscape
The dialysis vascular access market is an established but underserved segment. Synthetic grafts made from expanded polytetrafluoroethylene (ePTFE) are currently used when native fistulas fail or cannot be created, but they carry elevated rates of thrombosis and infection relative to mature fistulas. The ATEV is positioned as a biologic alternative that integrates with host tissue over time, potentially offering durability advantages over synthetic options.
No direct biological-graft competitor holds a current FDA approval in the AV access indication, though several academic and commercial groups have explored decellularised or bioengineered conduits at various preclinical and early clinical stages. If the supplemental BLA is accepted and reviewed on standard timelines, a decision could arrive in the second half of 2027, depending on whether the agency designates a priority review.
Humacyte's pipeline extends beyond dialysis access to peripheral artery disease and, in earlier-stage work, coronary artery bypass and paediatric cardiac surgery. The near-term regulatory and commercial focus, however, sits squarely on the haemodialysis indication, where an approval would meaningfully broaden the addressable market for Symvess, the brand name under which the ATEV is commercially available in the vascular trauma setting. Investors will look for the BLA acceptance letter and any indication of FDA review clock designation as the next material milestones.